ClinicalTrials.Veeva

Menu
S

San Diego Cardiac Center | San Diego, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tolvaptan
Ziltivekimab
Calcium
sodium
Milvexian
Pexelizumab
Inclisiran
EntrestoTM
carvedilol
Methotrexate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 39 total trials

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

The purpose of this study is to demonstrate the safety and 12-month effectiveness of the BWI OMNYPULSE™ pulsed field ablation (PFA) platform for pulm...

Enrolling
Atrial Fibrillation
Device: OMNYPULSE™ Catheter with the TRUPULSE Generator
Locations recently updated

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Drug: Milvexian
Other: Placebo

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Apixaban Placebo
Drug: Milvexian

The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Set...

Enrolling
Stroke
Patent Foramen Ovale
Device: AMPLATZER™ PFO Occluder

The Amulet™ device will be evaluated for safety and efficacy by demonstrating its performance is non-inferior to the commercially available WATCHMAN®...

Active, not recruiting
Stroke
Device: WATCHMAN Left Atrial Appendage Closure
Device: Amulet Left Atrial Appendage Occluder

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Not yet enrolling
Acute Myocardial Infarction (AMI)
Cardiovascular Risk
Drug: Placebo
Drug: Ziltivekimab

Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification...

Enrolling
Heart Valve Diseases
Degenerative Mitral Valve Disease
Device: Tendyne Mitral Valve System
Device: MitraClip System

The primary objective of this study is to collect sensor data from insertable cardiac monitor systems.

Active, not recruiting
Heart Failure
Device: Investigational LUX-Dx ICM Implant

It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved...

Enrolling
Heart Failure, Systolic
HFrEF - Heart Failure With Reduced Ejection Fraction
Drug: Placebo
Biological: SRD-001

Trial sponsors

Abbott logo
Biosense Webster logo
B
Boston Scientific logo
Janssen (J&J Innovative Medicine) logo
Novo Nordisk logo
Otsuka logo
V
Abbott logo
Alexion Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems